Quarterly Earnings Outperform Consensus Amid Global Market Headwinds
The consolidated financial earnings for the second quarter ended September 30 released by Dr Reddy's Laboratories provided substantial relief to domestic and international investors. Net profit after statutory taxes settled at 9.25 billion rupees (approximately $97.43 million), which, although lower than the 13.47 billion rupees booked a year earlier, easily surpassed the 7.49 billion rupees consensus projected by financial analysts.
This performance highlights the resilience of the Hyderabad-based pharmaceutical company's diversified revenue architecture. Consolidated revenue from operations contracted by only 1.6% to 86.98 billion rupees, effectively weathering a sharp 23% downturn in North American sales that fell to 24.89 billion rupees under severe generic price deflation.
The Indian market remained a bright spot with revenue boosted by demand for chronic therapy drugs across broad healthcare networks.
















